At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 104 enrolled
Drug / intervention
Brigatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating Brigatinib for ALK-positive Advanced NSCLC. Completed, enrolled 104 participants across 33 sites.
Detailed Summary
The purpose of this study is to evaluate efficacy and safety of brigatinib in Japanese participants with anaplastic lymphoma kinase (ALK)-positive NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsALK-positive Advanced NSCLC
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartJan 2018
Primary CompletionSep 2020
Study CompletionJul 2021
TodayJul 2026
First PostedJan 25, 2018
Enrollment StartJan 29, 2018
Primary CompletionSep 29, 2020
Study CompletionJul 28, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.4 years ago
Interventions
Brigatinibdrug
Brigatinib tablet